



IMPORTANT CORPORATE ANNOUNCEMENT

1. **PPLPHARMA** : CO. Unit Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP.
2. **RPPINFRA** : CO. Wins New Orders Worth RS.28.77CR.
3. **WAAREEENER** : CO. Unit has started its Commercial Production of 1.6GW Module line at Brookshire, Texas, USA.
4. **KESAR PETROPRODUCTS** : CO. Commences water trials to enhance the production capacity at the 6,000-ton fertilizer in its New Plant located in Ratnagiri, Maharashtra.
5. **ZYDUSLIFE** : CO. Announces USFDA Orphan Drug Designation to Usnoflast for the treatment of Amyotrophic Lateral Sclerosis (ALS).
6. **INFOBEAN** : CO. Achieves Prestigious CMMI Level 5 Appraisal for Development.
7. **TERASOFT** : CO. Received Advance Work order worth RS.5104CR.
8. **HINDUNILVR** : CO. Acquires Palm Undertaking to Enhance Local Supply Chain.
9. **FCL** : CO. Inaugurates Modern Workspace in Mumbai, Strengthening Growth and Operational Excellence.
10. **VTL** : CO. Approved RS.330CR. Investment to modernize and Upgrade machines in its Spinning Units, enhancing efficiency and Productivity.
11. **HUDCO** : CO. Signs MOU with Vadhvan Port Project; CO. to Provide funds up to RS.250B. for VPPL Projects.
12. **LTIM** : CO. Renews its Strategic Alliance with the Association of American Medical Colleges.
13. **ITI** : CO. Wins Aaple Sarkar Seva Kendra Order Worth RS.167CR. in Maharashtra.



IMPORTANT CORPORATE ANNOUNCEMENT

- 14. TRISHAKTI INDUSTRIES** : CO. Secures RS.60M. Contract from NCC.
- 15. ROHLTD** : CO. Expands Portfolio with Increased room Inventory in Regenta Suites Gurgaon.

MAJOR UPCOMING RESULTS

1. <u>ADANIENSOL</u>	23-JAN-25
2. <u>ADANIGREEN</u>	23-JAN-25
3. <u>CYIENT</u>	23-JAN-25
4. <u>DRREDDY</u>	23-JAN-25
5. <u>HINDPETRO</u>	23-JAN-25
6. <u>IEX</u>	23-JAN-25
7. <u>INDUSTOWER</u>	23-JAN-25
8. <u>MPHASIS</u>	23-JAN-25
9. <u>SONACOMS</u>	23-JAN-25
10. <u>SYNGENE</u>	23-JAN-25
11. <u>UNITDSPR</u>	23-JAN-25
12. <u>ULTRACEMCO</u>	23-JAN-25



IMPORTANT CORPORATE ANNOUNCEMENT

DISCLAIMER

This document has been prepared by CLIMB CAPITAL SERVICES PVT LTD ("the Company") for informational purposes only. The contents of this booklet are not intended to be, and must not be construed as, an offer, invitation, or solicitation to buy or sell any securities. The Company does not provide personalized investment advice or recommendations.

No Buy or Sell Recommendation:

The information presented in this booklet is for general knowledge and discussion purposes only. CLIMB CAPITAL SERVICES PVT LTD does not endorse or recommend any specific investment strategies or actions. Clients are advised to exercise their own judgment and consult with their financial advisors before making any investment decisions.

The analyses, opinions, and views expressed in this booklet are based on the Company's independent assessment and research. We do not receive any compensation from any issuer for providing this information.

No Warranty or Guarantee:

While the Company strives to ensure the accuracy and reliability of the information presented, we do not make any warranties or representations, express or implied, regarding the completeness, accuracy, or suitability of the information. Clients should independently verify the information before relying on it.

Investment Risks:

Investing in securities involves inherent risks, and past performance is not indicative of future results. The value of investments may fluctuate, and investors may lose some or all of their invested capital. CLIMB CAPITAL SERVICES PVT LTD is not liable for any financial losses incurred as a result of investments made based on the information provided in this booklet.

Confidentiality:

This booklet is confidential and intended solely for information purpose. Reproduction or distribution of this document without the Company's prior written consent is strictly prohibited.

By accessing this booklet, you agree to the terms and conditions outlined herein. CLIMB CAPITAL SERVICES PVT LTD reserves the right to modify or update this disclaimer without prior notice.

For any clarification or further information, please contact our client services team. Thank you for your understanding and cooperation.

Sincerely,